What Pyralgina Treats: Main Uses and Benefits

Pyralgina (Sodium Metamizole/Dipyrone) is commonly used to provide supportive symptomatic relief across domains involving symptoms related to physical discomfort, heightened physiological activity, and systemic imbalance. The medicine is utilized in conditions where additional symptomatic support is needed.

The medicine is applied across therapeutic areas to help manage acute, severe pain episodes; visceral pain linked to symptoms related to heightened muscular activity, such as renal or biliary colic; and high, persistent fever that may be difficult to manage when symptoms become more disruptive during flare-ups. The supportive action helps patients cope more steadily with difficult episodes, contributing to easing the overall symptom load.

The medicine is relevant for managing symptom clusters that may become intense or disruptive.

---

Quick Fact: Relief for Acute Symptoms

Pyralgina is considered relevant in clinical settings involving acute visceral pain, where relief is sought from discomfort caused by symptoms related to heightened muscular activity in internal organs. It is applied in scenarios where additional management of discomfort is required during episodes of colic.

Regulatory References

1. European Medicines Agency

Who Can and Cannot Use Pyralgina? (Metamizole)

The eligibility for Pyralgina is strictly defined by regulatory authorities and centers on absolute contraindications, age limits, and physiological status.

---

Absolute Non-Eligibility (Contraindicated)

Official labeling contraindicates the use of Metamizole in several patient populations:

• Individuals with a history of agranulocytosis induced by Metamizole or related pyrazolone medicines.
• Patients with impaired bone marrow function or established diseases of the haematopoietic system.
• Patients with known analgesic-induced asthma or hypersensitivity reactions to non-narcotic analgesics.
• Infants below the age of 3 months or those weighing less than 5 kg.
• Women in the third trimester of pregnancy.
• Patients with acute intermittent hepatic porphyria or genetic G6PD deficiency.

---

Restricted and Conditional Use

Use is subject to limitations in specific groups:

• Children and Adolescents (3 months to 14 years): Eligibility is affirmed but requires strict body weight-based dosing; fixed-dose oral tablets are typically not recommended.
• Pregnancy (First and Second Trimester): Use is restricted; may only be acceptable for single doses if other analgesic options are unsuitable.
• Lactation: Use is not recommended; official guidance advises discarding breastmilk for 48 hours following a single dose.
• Organ Impairment: Patients with impaired renal or hepatic function must avoid multiple high doses, as use is not established for long-term treatment in severe cases.

---

The regulatory profile establishes clear exclusions based on age, blood disorders, and pregnancy status, ensuring the medicine is used only within officially established population boundaries.

Pyralgina (Sodium Metamizole) interactions are primarily defined by its effect on drug metabolism. Regulatory documentation identifies Metamizole as a moderate to strong inducer of several liver enzymes, including CYP3A4, CYP2B6, and CYP2C19. This pharmacokinetic interaction enhances the clearance of co-administered medicines that are substrates for these enzymes. This formally results in decreased plasma concentrations for certain drugs, such as the antifungal Voriconazole and the immunosuppressant Ciclosporin, which may reduce their effectiveness. Conversely, Metamizole may decrease the excretion rate of substances like Allopurinol, resulting in increased serum levels.

A key pharmacodynamic interaction involves Acetylsalicylic acid (Aspirin), where co-administration inhibits the antiplatelet effect. To manage this documented interference, regulatory labeling specifies a mandatory timing rule: Aspirin should be taken at least 30 minutes prior to Metamizole intake. The co-administration with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is also associated with an increased risk of nephrotoxicity. Interaction-related restrictions include a formal contraindication for use during the last three months of pregnancy and caution during high-dose use.

Pyralgina is the trade name for the pro-drug metamizole, which undergoes non-enzymatic hydrolysis to its active metabolite, 4-methyl-amino-antipyrine (MAA), and further metabolism to 4-amino-antipyrine (AA). These metabolites preferentially distribute into the central nervous system (CNS).

The primary molecular target is the cyclooxygenase-3 (COX-3) enzyme, a splice variant of COX-1, predominantly located in the CNS. MAA and AA act as inhibitors of COX-3, which reduces the synthesis of prostanoids, specifically prostaglandin E2 (PGE2), within the brain and spinal cord. This decreased PGE2 concentration modulates neuronal excitability in pain pathways and centrally regulates the hypothalamic thermoregulatory set point.

In a secondary pathway, the active metabolite AA acts as an agonist at central cannabinoid receptor type 1 (CB1) receptors. Activation of CB1 receptors initiates the descending antinociceptive system, disinhibiting activating neurons via reduced GABAergic transmission. Furthermore, a peripheral mechanism involves the L-arginine/nitric oxide/cGMP pathway, where metabolites induce delayed activation of ATP-sensitive potassium (KATP) channels on peripheral tissues, leading to smooth muscle relaxation.

How to Use Pyralgina: Administration Guidelines

Pyralgina, which contains Sodium Metamizole (Dipyrone), is used according to instructions detailing the route, dosage limits, and frequency. The medicine is available in various forms and administration routes, including oral (tablets or drops), rectal (suppositories), and parenteral (intramuscular and intravenous injection).

Dosing and Frequency

Administration commences with the lowest effective dose to manage symptoms, adhering to established maximums. For adults (typically 15 years or older), the maximum single oral dose is 1,000 mg, and the maximum daily oral dose is 4,000 mg. Dosing frequency is constrained by a required interval of 6 –8 hours between single doses, allowing for administration up to four times daily.

Age-Specific and Procedural Instructions

Dosage for pediatric patients (under 15 years) is determined based on body weight (kilograms), with a typical single dose of 8 –16 mg of metamizole per kg of body weight. For the injectable solution, administration is performed as a slow intravenous (IV) injection or infusion. This parenteral form is intended for short-term treatment of severe symptoms. The time to the expected clinical effect after oral administration is 30 to 60 minutes, which informs the overall use pattern.

Research Evidence / Overview of Studies for Pyralgina

The research base for Pyralgina (Sodium Metamizole/Dipyrone) is made up of different types of clinical investigations, including Randomized Controlled Trials (RCTs) and comprehensive analyses called Systematic Reviews and Meta-analyses. This overview describes what researchers have studied and what the findings, according to official sources, indicate about this medicine.

---

Evidence for Use in Acute, Severe Postoperative Pain

Research exploring how symptoms change over time after surgery primarily involved short-term RCTs and systematic reviews focusing on adults. These studies monitored outcomes related to physical discomfort, specifically measuring pain intensity scores and the subsequent need for additional pain relief medication. Studies monitored changes in patient-reported pain intensity measurements over brief observation periods, typically within the first 24 hours following surgery. The designs of some trials involved using other active comparators or a placebo. The main research limitation frames here involve the follow-up durations were limited. Evidence provides context but not individual predictions for the management of discomfort beyond the immediate acute postoperative phase.

---

Evidence for Managing Acute Visceral Pain

This research examined the medicine's application in conditions associated with acute or disruptive episodes, such as pain linked to renal or biliary colic. The studies monitored outcomes related to episodic or acute changes in patient comfort, with researchers measuring changes in pain intensity scores at very short intervals. Findings describe patterns related to the time taken for patients to report changes in their discomfort levels. It should be noted that findings were mixed in some comparative trials when Metamizole was associated with certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), suggesting variability depending on the precise dose and administration route used. The follow-up durations were limited to the immediate 1-2 hours of the acute episode, providing limited information about long-term outcomes or recurrence.

---

Evidence for the Management of High Fever

Research on Metamizole's properties relevant to antipyresis was evaluated in Randomized Controlled Trials and Meta-analyses. These studies explored outcomes linked to systemic or functional imbalance, primarily monitoring absolute body temperature reduction at specific time intervals. Study populations included both febrile adults and children whose high fever was being monitored. Research describes patterns related to fever management outcomes that were monitored across both adult and pediatric cohorts. Limited information for long-term outcomes is available, and comparative evidence is lacking for the medicine's action during the immediate onset period against all other available antipyretics.

---

Key Limitations and Areas of Research Uncertainty

The evidence highlights what is known and what is still uncertain about this medicine. The clinical evidence for Pyralgina is primarily derived from research focusing on episodic or acute changes. Therefore, long-term effects are not fully established and there is limited information for long-term outcomes regarding maintenance or chronic symptom management. The results apply only to the populations studied and under the specific conditions of the trials, and research does not determine whether an individual will respond similarly.

Key Studies & References

1. Efficacy and safety of metamizole in relieving acute visceral pain: a systematic review

Common questions about Pyralgina (FAQ)

Q: How long does the effect of Pyralgina last in the body?

A: Official documents indicate that the analgesic (pain-relieving) effect of the medicine typically lasts for about four hours. This duration is one of the factors that informs the minimum required time interval between single doses. The dosing frequency should be based on the authorized instructions.

Q: Is Pyralgina considered a strong painkiller?

A: Official product information states that the active ingredient, Metamizole, is authorized for the treatment of moderate to severe pain. This classification confirms its use for symptoms that require effective relief.

Q: What are the most commonly reported side effects of Pyralgina?

A: While the full safety profile includes rare, serious risks, official documentation indicates that commonly reported adverse events can include low blood pressure (hypotension), dizziness, nausea, vomiting, headache, and rash. Patients are advised to refer to the medicine's Patient Information Leaflet for a complete list.

Q: What does 'contraindication' mean when discussing Pyralgina?

A: The term 'contraindication' refers to a specific condition or situation where a medicine must absolutely not be used. Using the medicine despite a contraindication is strongly discouraged due to the potential for serious harm.

Q: What are the official uses of Pyralgina according to regulatory bodies?

A: According to regulatory bodies, the official uses for this medicine include the treatment of moderate to severe pain, high fever, and certain types of pain that may be related to cancer. Official regulatory uses include the management of acute, high-level symptoms.

Q: What is the general safety classification of Pyralgina?

A: Regulatory bodies generally conclude that the benefits of the medicine continue to outweigh its risks, provided that the known risk of agranulocytosis is carefully managed. This profile relies on adherence to the warnings and restrictions provided in the official documentation.

Q: Is the onset of action different between the tablet and liquid forms of Pyralgina?

A: Official regulatory information provides a time frame for the expected onset of effect for all oral administration routes (tablets or drops), which is typically 30 –60 minutes. The authorized product information does not usually differentiate a precise variation in onset time between the solid tablets and liquid drops.

Q: Is it normal to feel a bit dizzy after taking Pyralgina?

A: Yes, dizziness (sometimes described as vertigo) is listed in official regulatory documents as a potential adverse event of the medicine. If this effect occurs, exercising caution when engaging in activities such as driving may be necessary.

Q: Why might a doctor prescribe Pyralgina over other painkillers?

A: Regulatory and authoritative reviews suggest this medicine offers a unique profile due to its strong analgesic and fever-reducing properties combined with a spasmolytic effect. The spasmolytic effect (smooth muscle relaxation) makes it a valuable choice for certain types of pain, such as those related to internal organ spasms or colic.

Q: Do children typically use Pyralgina for pain relief?

A: Yes, this medicine is authorized for use in pediatric patients starting from 3 months of age or those weighing over 5 kilograms. Official guidelines require that dosing for children be calculated strictly based on the child's body weight.

Q: Does Pyralgina contain ibuprofen or paracetamol?

A: The medicine only contains Sodium Metamizole as its single active ingredient. According to the official composition listed in regulatory documents, it does not contain ibuprofen or paracetamol (acetaminophen).

Q: Can Pyralgina be taken on an empty stomach?

A: Regulatory information suggests that the absorption of the active ingredient is generally not significantly affected by food intake. This means the medicine can typically be taken with or without food.

Q: Does Pyralgina have any known interaction with oral contraceptives?

A: Yes, official product information indicates that Metamizole can act as an enzyme inducer (e.g., CYP3A4). This metabolic effect can potentially decrease the concentration and therefore the effectiveness of co-administered oral contraceptive medications.

Q: How does the structure of Pyralgina's active ingredient differ from acetaminophen?

A: The active ingredient in this medicine, Metamizole, is classified as a pyrazolone derivative, which is a specific type of chemically synthesized compound. This chemical class is distinct from the structure of drugs like acetaminophen.

Q: Why do some people refer to Pyralgina as Novalgin?

A: Novalgin is another common brand name under which the same active ingredient, Metamizole, is or has been marketed in various countries.

Q: Can Pyralgina be used alongside topical pain relief creams?

A: Regulatory documents focus primarily on interactions involving systemic absorption of other drugs. Topical pain relief creams are generally not listed as a significant interaction risk unless the product is known to be absorbed systemically in large quantities.

Q: Can older adults typically use Pyralgina?

A: Official guidelines advise that use in older adults requires caution, as the risk of certain serious side effects, such as agranulocytosis, may be increased. Use requires careful consideration and monitoring.

Q: Is Pyralgina typically used for headaches or migraines?

A: Yes, the medicine is commonly used to treat pain, including acute pain associated with migraine headaches. Its use is authorized for the general treatment of moderate to severe pain.

Q: Does Pyralgina contain lactose or gluten?

A: Regulatory documents that list excipients indicate that many oral tablet formulations of Metamizole contain lactose. Information about excipients like lactose or gluten is detailed in the specific Patient Information Leaflet for each formulation.

Q: Can I become dependent on Pyralgina if I take it regularly?

A: This medicine is classified as a non-opioid analgesic. According to regulatory classifications, it is not typically associated with the risk of physical dependency seen with opioid medications.

Q: Can Pyralgina be used for menstrual cramps?

A: While menstrual cramps are not an explicitly listed indication, the official uses include general pain and the treatment of smooth muscle spasms. This spasmolytic property makes it relevant for addressing this type of discomfort.

Q: Does Pyralgina interact with antidepressant medications?

A: Yes, Metamizole can act as an enzyme inducer, meaning it may interfere with the metabolism of certain antidepressant medications. This interference could potentially decrease the concentration and effectiveness of the antidepressant.

Q: Can Pyralgina be taken with other heart medications?

A: Yes, it can interact with several types of cardiovascular or heart medications. Specifically, official product information mentions potential interactions with certain oral anticoagulants (blood thinners) and anti-hypertensive drugs (blood pressure medicines).

Q: Do studies support the use of Pyralgina for musculoskeletal pain?

A: Regulatory approval is generally for moderate to severe pain. Although specific studies on musculoskeletal pain are not universally highlighted in main summaries, the medicine may be used for general acute pain in a clinical setting based on its analgesic effect.

Q: Does taking Pyralgina cause drowsiness?

A: Yes, drowsiness (also called somnolence) is listed in the regulatory documents as a potential adverse event of the medicine. This effect is generally considered uncommon.

Q: What happens if I miss a scheduled time for Pyralgina?

A: Official advice for a missed dose is typically to only take the dose when you remember, provided the required time interval from the last dose is respected. The guidance provided in official documents states never to double the next dose to compensate for the one missed.

Q: Are there any specific foods to avoid when using Pyralgina?

A: Regulatory documents generally do not advise avoiding specific foods while taking this medicine. This is because the medicine’s absorption profile is typically not significantly altered by food intake.

Q: Is there a known interaction between Pyralgina and alcohol?

A: Yes, regulatory documents advise that the combination of this medicine with alcohol should typically be avoided. Combining the two may lead to an increased risk of specific adverse effects.

Q: Are there any documented interactions between Pyralgina and caffeine?

A: Metamizole may interact with the way the body metabolizes caffeine (CYP1A2 enzyme). Regulatory labels often advise caution as this effect could potentially alter the expected effects of caffeine.

Q: Does the packaging of Pyralgina include a patient information leaflet?

A: Yes, regulatory requirements worldwide mandate that all authorized prescription and over-the-counter medicines must include a Patient Information Leaflet (PIL). This document provides detailed information on the product's safe use and safety profile.

Q: Is Pyralgina known to interact with herbal remedies like St. John's Wort?

A: Caution is often advised regarding combining this medicine with herbal remedies such as St. John's Wort. Regulatory labels note that these combinations carry a risk of complex enzyme-mediated drug interactions.

How to Store and Dispose of Pyralgina

Official regulatory documents define the storage and disposal requirements for Pyralgina (Sodium Metamizole) to ensure product stability and safety.

Storage Requirements

Pyralgina must be stored at a temperature below 25 C. The product must be kept in its original container and be tightly closed to protect the contents from light and moisture. It is mandatory to keep the medicine out of the sight and reach of children and store it locked up.

Condition	Requirement
Temperature	Below 25 C
Container	Kept tightly closed in original packaging
Stability	Do not use after expiry date; 28 days for opened injection solution

Disposal Instructions

Unused or expired Pyralgina must not be disposed of via wastewater or regular household trash. Regulatory guidance requires that the product be taken to a pharmacist or an approved waste collection point to ensure proper environmental handling, as it should not be released into the environment.